Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent
Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of glioma
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)
First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic
Telix announces first two patients dosed in phase I trial of lung & ovarian cancer theranostic
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
Telix announces it has entered into a strategic collaboration agreement with Varian Medical Systems
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product
FDA Grants Orphan Drug Designation for TLX102
Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of multiple myeloma.
First Patient Dosed in Renal Cancer Imaging Study in Japan
Telix announces the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx in Japan
Telix H1 2020 Results and Company Update Conference Call
Telix will hold an investor conference call to present the Company’s H1 2020 financial results together with an update on Telix’s operations.
Drug Master File for Glioblastoma Therapy Product Filed with FDA
Telix announces it has submitted a Drug Master File to the FDA for TLX101 (4-[131I]Iodol-phenylalanine injection)
Activities Report and Sales Note to Accompany Appendix 4C
Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales update